The stock's sharp rise during regular market hours on February 3, 2026, builds on the January 29 announcement of Belite Bio's participation in the Asia-Pacific Academy of Ophthalmology Congress (APAO) scheduled for February 5-7 in Hong Kong. There, the company will deliver an oral presentation on February 6 detailing topline results from the pivotal Phase 3 DRAGON trial of tinlarebant for adolescent Stargardt disease, which previously showed a 36% reduction in retinal lesions in December 2025 topline data. This event amplifies trader optimism ahead of a planned NDA filing in the first half of 2026, corroborated by elevated trading volume and social media discussions noting all-time highs. Recent analyst initiations in late January, including Buy ratings with targets up to $195, further support the momentum as investors position for potential regulatory progress.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.